In another MR study [38], inconsistent findings regarding the impact of PCSK9 inhibitors on tumors, particularly gastric cancer, lung cancer, and hepatocellular carcinoma, were noted. This evidence concerns the gene PCSK9 and hepatocellular carcinoma.